[CGEN] Compugen Ltd.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 5.25 Change: 0.1 (1.94%)
Ext. hours: Change: 0 (0%)

chart CGEN

Refresh chart

Strongest Trends Summary For CGEN

CGEN is in the long-term down -79% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Compugen Ltd., a therapeutic product discovery company, is engaged in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company?s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 fusion protein candidates for the treatment of autoimmune diseases and inflammatory conditions, such as multiple sclerosis and rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, CGEN-15022, and CGEN-15049; and CGEN-671, a novel antibody-drug conjugate. Compugen Ltd. was incorporated in 1993 and is headquartered in Tel Aviv, Israel.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities72.13 M Cash From Investing Activities-64.09 M Cash From Operating Activities-11.15 M Gross Profit130 K
Net Profit-6.14 M Operating Profit-6.32 M Total Assets108.48 M Total Current Assets68.55 M
Total Current Liabilities5.24 M Total Debt Total Liabilities7.52 M Total Revenue510 K
Technical Data
High 52 week4.7 Low 52 week2.35 Last close3.17 Last change2.44%
RSI52.4 Average true range0.22 Beta0.71 Volume73.51 K
Simple moving average 20 days0.04% Simple moving average 50 days-7.51% Simple moving average 200 days-11.85%
Performance Data
Performance Week-7.17% Performance Month2.44% Performance Quart-12.07% Performance Half-5.51%
Performance Year24.14% Performance Year-to-date26.62% Volatility daily4.42% Volatility weekly9.89%
Volatility monthly20.27% Volatility yearly70.2% Relative Volume296.09% Average Volume219.16 K
New High New Low

News

2019-03-12 07:46:00 | Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate

2019-03-08 10:04:03 | Achillion ACHN Reports Narrower-Than-Expected Loss in Q4

2019-03-07 09:09:02 | Compugen CGEN Upgraded to Strong Buy: What Does It Mean for the Stock?

2019-03-07 09:06:02 | Merrimack MACK Incurs Narrower-Than-Expected Loss in Q4

2019-03-05 07:00:00 | Compugen to Present at the Cowen and Company 39th Annual Health Care Conference

2019-03-01 07:00:00 | Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium

2019-02-26 02:00:00 | Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations

2019-02-14 07:00:00 | Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET

2019-01-22 07:00:00 | Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy

2019-01-16 07:07:39 | How Much Of Compugen Ltd. NASDAQ:CGEN Do Institutions Own?

2019-01-14 07:00:00 | Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium

2018-11-23 08:20:00 | New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-13 07:00:00 | Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy

2018-11-07 08:20:01 | Compugen CGEN Reports Q3 Loss

2018-11-07 07:20:19 | Compugen: 3Q Earnings Snapshot

2018-11-07 07:00:00 | Compugen Reports Third Quarter 2018 Results

2018-11-05 05:35:10 | Compugen Ltd. CGEN Sees Hammer Chart Pattern: Time to Buy?

2018-10-24 07:15:00 | Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET

2018-10-12 15:09:27 | Don't Fixate On Market Woes, Just Make Your Trades

2018-10-12 10:25:02 | Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

2018-10-12 09:30:01 | Bristol-Myers Inks Deal and Invests $12 Million in Compugen

2018-10-11 07:32:00 | Compugen's stock shoots up after Bristol-Myers to pay 52% premium for equity stake

2018-10-11 07:00:00 | Bristol-Myers to invest in Compugen, collaborate in clinical trials

2018-10-11 06:59:00 | Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors

2018-09-20 07:00:00 | Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial

2018-09-14 13:27:45 | Should You Have Compugen Ltd’s NASDAQ:CGEN In Your Portfolio?

2018-09-07 07:00:00 | Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial

2018-09-05 07:00:00 | Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors

2018-08-01 07:28:24 | Compugen: 2Q Earnings Snapshot

2018-08-01 07:00:00 | Compugen Reports Second Quarter 2018 Results

2018-08-01 06:30:00 | Compugen Ltd. to Host Earnings Call

2018-07-18 07:00:00 | Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET

2018-07-02 09:10:15 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-02 07:05:00 | Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254

2018-07-02 07:00:00 | Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody

2018-06-27 12:38:55 | When Should You Buy Compugen Ltd NASDAQ:CGEN?

2018-06-15 07:00:00 | Compugen Announces $21 Million Registered Direct Offering of Ordinary Shares and Warrants

2018-06-11 07:00:00 | Compugen Announces the Appointment of New Board Members

2018-05-16 08:53:12 | Market Has Not Yet Noticed Potential in Compugen; Have You?

2018-05-09 07:58:19 | Compugen: 1Q Earnings Snapshot

2018-05-09 07:00:00 | Compugen Reports First Quarter 2018 Results

2018-05-02 19:14:18 | Compugen Ltd NASDAQ:CGEN: Should The Recent Earnings Drop Worry You?

2018-04-30 07:00:00 | Compugen First Quarter 2018 Conference Call Scheduled for Wednesday, May 9, 2018 at 10:00 AM ET

2018-04-27 07:24:00 | Compugen Reports on Status of Investigational New Drug Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody

2018-04-19 07:40:00 | Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer Immunotherapy

2018-04-17 07:00:00 | Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy

2018-04-03 01:00:28 | [$$] AstraZeneca receives regulatory boost for oncology drugs

2018-04-02 10:04:09 | Benzinga Pro's 5 Stocks To Watch Today

2018-04-02 07:25:00 | Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products

2018-04-02 07:01:32 | Compugen, AstraZeneca unit in cancer drug development deal